List of Bryhali drug patents

Bryhali is owned by Bausch.

Bryhali contains Halobetasol Propionate.

Bryhali has a total of 2 drug patents out of which 0 drug patents have expired.

Bryhali was authorised for market use on 06 November, 2018.

Bryhali is available in lotion;topical dosage forms.

Bryhali can be used as topical treatment of plaque psoriasis in adults.

The generics of Bryhali are possible to be released after 02 November, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10478502 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(8 years from now)

US8809307 BAUSCH Pharmaceutical formulations containing corticosteroids for topical administration
Nov, 2031

(8 years from now)

Drugs and Companies using HALOBETASOL PROPIONATE ingredient

Market Authorisation Date: 06 November, 2018

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: LOTION;TOPICAL

How can I launch a generic of BRYHALI before it's patent expiration?
More Information on Dosage

BRYHALI family patents

7

United States

2

Canada

2

Korea, Republic of

1

Israel

1

Russia

1

Japan

1

Brazil

1

Mexico

1

Australia

1

New Zealand

1

China

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic